A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

NCT07090954 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: GR1803 injection
DRUG: Anti-CD38 Monoclonal Antibody

Sponsor

Genrix (Shanghai) Biopharmaceutical Co., Ltd.